Exelixis Announces Positive Results from STELLAR-303 Phase 3 Trial: Zanzalintinib and Atezolizumab Improve Survival in Metastatic Colorectal Cancer
I'm PortAI, I can summarize articles.
Exelixis Inc. announced positive results from the STELLAR-303 Phase 3 trial, showing that the combination of zanzalintinib and atezolizumab significantly improves overall survival in patients with previously treated metastatic colorectal cancer compared to regorafenib. The company plans to discuss these results with regulatory authorities and present detailed findings at a medical conference. The safety profile of the drug combination remains consistent with prior observations, with no new safety signals identified.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments